PHASE I STUDY OF PHOTODYNAMIC THERAPY FOR SURFACE MALIGNANCIES

光动力疗法涉及使用光活化化合物， 定位于肿瘤中，随后该化合物被光激活 用于治疗癌症的细胞毒性作用。当前协议 使用静脉注射Photofrin II制剂， 血卟啉衍生物，目前唯一批准的光敏剂 用于人类。接下来是向受影响的人提供光 区域使用耦合到氩/泵浦染料激光器的光纤。 血卟啉衍生物选择性地定位于肿瘤中， 某些正常组织光敏剂的选择性保留 与聚焦光传递到所涉及的区域的组合允许 选择性破坏肿瘤，对未累及的正常组织影响最小 组织.血卟啉衍生物光动力疗法可能是临床上 可用于肿瘤累及的许多解剖部位。

Photodynamic therapy involves the use of a light activated compound which localizes in tumor, followed by the activation of this compound by light for cytotoxic effects for the treatment of cancer. The current protocol uses the intravenous administration of the Photofrin II preparation of the hematoporphyrin derivative, the only currently approved photosensitizer for use in humans. This is followed by the delivery of light to the affected area using optical fibers coupled to an argon/pumped dye laser. Hematoporphyrin derivative selectively localizes in tumor compared to certain normal tissues. Selective retention of the photosensitizer in combination with focal light delivery to the involved area permits selective destruction of tumor with minimal effect on uninvolved normal tissue. Hematoporphyrin derivative photodynamic therapy may be clinically useful in a number of anatomic sites involved by tumor.